Alterations in signaling in the FGF/FGFR2 pathway (e.g., overexpression of FGFR2 protein or amplification of FGFR2 gene) have been associated with GEA, breast, and other cancers and with a decreased prognosis [6, 8–11], suggesting that inhibition of FGFR2 may be a rational target for cancer therapy [12, 13]. Here, FGFR2 is linked to cancer.